Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEAD3 | Q99594 | 2/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.39 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | GBA1 | P04062 | 1/20 | 0.34 |
| ▸ | UGCG | Q16739 | 1/20 | 0.34 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.34 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10080603 | 0.86 | SOAT1 (0.33) | ADRA1DADRA1AADRA1BKDM4EALDH1A1 | |
| SCHEMBL16749902 | 0.86 | ADRA1D (0.44) | TEAD3ADRA1DADRA1AADRA1BMEN1 | |
| SCHEMBL12816498 | 0.86 | ADRA1D (0.44) | TEAD3ADRA1DADRA1AADRA1BMEN1 | |
| SCHEMBL12816036 | 0.86 | SCN1A (0.42) | MEN1KMT2AHRH3KDM4EALDH1A1 | |
| SCHEMBL30679185 | 0.86 | SCN1A (0.42) | MEN1KMT2AHRH3KDM4EALDH1A1 | |
| SCHEMBL15934399 | 0.85 | HRH3 (0.36) | TEAD3ADRA1DADRA1AADRA1BMEN1 | |
| SCHEMBL16749903 | 0.85 | ADRA1D (0.41) | TEAD3ADRA1DADRA1AADRA1BMEN1 | |
| SCHEMBL23912977 | 0.84 | L3MBTL1 (0.39) | TEAD3ADRA1DADRA1AADRA1BMEN1 | |
| SCHEMBL15934378 | 0.84 | TEAD3 (0.33) | TEAD3ADRA1DADRA1AADRA1BHRH3 | |
| SCHEMBL17502988 | 0.83 | ADRA1D (0.42) | TEAD3ADRA1DADRA1AADRA1BAOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10239833-B2 | Intermediates, their process and use in preparation of selective α1-adrenoceptor antagonists, Silodosin | MANKIND PHARMA LTD. (IN) | 2019-03-26 | — | — | US | disclosed |
| US-20180111901-A1 | Novel Intermediates, their Process And Use In Preparation of Selective a1-Adrenoceptor Antagonists, Silodosin | MANKIND PHARMA LTD. (IN) | 2018-04-26 | — | — | US | disclosed |
| EP-2984070-B1 | N-HALOALKYLINDOLINE INTERMEDIATES, THEIR PROCESS AND USE IN PREPARATION OF SILODOSIN AND ITS DERIVATIVES | MANKIND PHARMA LTD (IN) | 2018-01-17 | — | — | EP | disclosed |
| US-9862681-B2 | N-haloalkylindoline intermediates, their process and use in preparation of Silodosin and its derivatives | MANKIND RESEARCH CENTRE (IN) | 2018-01-09 | — | — | US | disclosed |
| US-20160046577-A1 | N-Haloalkylindoline Intermediates, Their Process And Use In Preparation of Silodosin And its Derivatives | MANKIND PHARMA LTD (IN) | 2016-02-18 | — | — | US | disclosed |
| EP-2984070-A1 | N-HALOALKYLINDOLINE INTERMEDIATES, THEIR PROCESS AND USE IN PREPARATION OF SILODOSIN AND ITS DERIVATIVES | Mankind Research Centre (IN) | 2016-02-17 | — | — | EP | disclosed |
| WO-2014167507-A1 | N-HALOALKYLINDOLINE INTERMEDIATES, THEIR PROCESS AND USE IN PREPARATION OF SILODOSIN AND ITS DERIVATIVES | MANKIND RESEARCH CENTRE (IN) | 2014-10-16 | — | — | WO | disclosed |
| WO-2014118606-A2 | A NOVEL PROCESS FOR THE PREPARATION OF SILODOSIN | ALEMBIC PHARMACEUTICALS LIMITED (IN) | 2014-08-07 | — | — | WO | disclosed |
| WO-2014118606-A2 | A NOVEL PROCESS FOR THE PREPARATION OF SILODOSIN | ALEMBIC PHARMACEUTICALS LIMITED (IN) | 2014-08-07 | — | — | WO | disclosed |
| EP-2172443-B1 | METHOD FOR PRODUCING OPTICALLY ACTIVE AMINE | HAMARI CHEMICALS LTD (JP) | 2013-03-27 | — | — | EP | disclosed |
| US-8222452-B2 | Method for producing optically active amines | HAMARI CHEMICALS, LTD. (JP) | 2012-07-17 | — | — | US | disclosed |
| WO-2012062229-A1 | A METHOD OF MANUFACTURING (-)-L-(3-HYDROXYPROPYL)-5-[(2R)-2-({2,2,2-TRIFLUOROETHOXY)- PHENOXYETHYL}AMINO)PROPYL]-2,3-DIHYDRO-LH-INDOLE-7-CARBOXAMIDE | ZENTIVA, K.S. (CZ) | 2012-05-18 | — | — | WO | disclosed |
| US-20100160636-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE AMINES | HAMARI CHEMICALS, LTD. (JP) | 2010-06-24 | — | — | US | disclosed |
| EP-2172443-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE AMINE | Hamari Chemicals, Ltd. (JP) | 2010-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10239833-B2 | Intermediates, their process and use in preparation of selective α1-adrenoceptor antagonists, Silodosin | ADRA1D, ADRB1, ADRA1A | TEAD3 1945/4885ADRA1D 1/4885ADRA1A 3/4885 |
| US-20160046577-A1 | N-Haloalkylindoline Intermediates, Their Process And Use In Preparation of Silodosin And its Derivatives | ADRA1D, ADRA1A, ADRB1 | TEAD3 2830/4885ADRA1D 1/4885ADRA1A 2/4885 |
| US-20180111901-A1 | Novel Intermediates, their Process And Use In Preparation of Selective a1-Adrenoceptor Antagonists, Silodosin | ADRA1D, ADRA1A, ADRB1 | TEAD3 2033/4885ADRA1D 1/4885ADRA1A 2/4885 |
| US-20100160636-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE AMINES | INMT, HNMT, PADI3 | TEAD3 2177/4885ADRA1D 1633/4885ADRA1A 1737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.